VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE)

32 filings reported holding VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share as of Q2 2024.
VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) has 29 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 7.94M shares of 16.7M outstanding shares and own 47.67% of the company stock.
Largest 10 shareholders include Cormorant Asset Management, LP (1.39M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.39M shares), CITADEL ADVISORS LLC (1.21M shares), DSC Advisors, L.P. (696K shares), SILVERARC CAPITAL MANAGEMENT, LLC (467K shares), Palo Alto Investors LP (445K shares), VANGUARD GROUP INC (444K shares), Exome Asset Management LLC (353K shares), Parkman Healthcare Partners LLC (345K shares), and AlphaCentric Advisors LLC (311K shares).
This table shows the top 29 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.